spiration, inc. dba olympus respiratory america

What spiration, inc. dba olympus respiratory america does

Spiration, Inc., doing business as Olympus Respiratory America, is a US medical device subsidiary of Olympus America Inc. (the US operating arm of Japan's Olympus Corporation). The company develops, manufactures, and commercializes the Spiration Valve System, an FDA-approved (PMA, December 2018) endobronchial valve therapy for the treatment of severe emphysema. The system uses small, umbrella-shaped one-way valves made from nitinol (nickel-titanium alloy) with miniature airway anchors, delivered via bronchoscope in a minimally invasive procedure that redirects air from diseased lung tissue to healthier regions, reducing hyperinflation. Each procedure uses on average four valves, and clinical evidence from the EMPROVE trial demonstrates clinically meaningful improvements in lung function (12.1% FEV1), dyspnea (29.6% mMRC reduction), and quality of life (9.5-point SGRQ improvement).

The business operates a sales-led, physician-driven commercial model targeting US pulmonologists and the hospital systems where they practice. Revenue is generated through hardware sales of the valve system to healthcare facilities, which in turn bill insurers for the procedure and device. Coverage has been progressively expanded across major US payers including UnitedHealthcare, Anthem Blue Cross and Blue Shield, Blue Cross and Blue Shield of North Carolina, Medical Mutual of Ohio, Highmark Blue Cross Blue Shield, and Health Care Service Corporation. Supporting tools include a Patient Eligibility Screener and a Physician Finder service on the company website, along with patient education content and partnerships with the COPD Foundation and Emphysema Foundation of America. The product portfolio is intentionally narrow: a single core device with a single approved indication in a single geography (United States), positioned as a minimally invasive alternative to lung volume reduction surgery or transplant for severe emphysema patients who have not achieved adequate relief from medication and pulmonary rehabilitation.

Name

spiration, inc. dba olympus respiratory america

Legal name

Spiration, Inc.

Website

https://spirationvalve.com

Company type

Private

Operating status

Operating

Short description

Spiration, Inc. dba Olympus Respiratory America is a US Olympus subsidiary that markets the FDA-approved Spiration Valve System, an endobronchial valve for severe emphysema delivered bronchoscopically. It sells the device to US pulmonologists and hospitals, reimbursed by major commercial insurers.

Ownership category

akta.pro rank

Product category

Respiratory Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Airway Management Devices (ET Tubes, LMAs, Tracheostomy, Suction) (HLAHAGAF)

Keywords

• Endobronchial valve therapy
• Severe emphysema treatment
• Bronchoscopic lung volume reduction
• Respiratory medical devices
• Interventional pulmonology

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Medical Device Sales: Revenue is generated through the sale of the Spiration Valve System to healthcare facilities and hospitals where the procedure is performed. The procedure involves placing multiple valves per patient (on average 4 valves). Healthcare facilities bill insurance for the procedure and device.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Spiration, Inc. dba Olympus Respiratory America sells the FDA-approved Spiration Valve System, an endobronchial valve therapy for patients with severe emphysema. The system consists of small umbrella-shaped one-way valves made of nitinol that are placed bronchoscopically in targeted airways to redirect air from diseased lung regions to healthier ones, reducing hyperinflation and improving breathing. On average, four valves are implanted per procedure, and the devices are sold to hospitals and specialty clinics where pulmonologists perform the implantation.

Product overview

The Spiration Valve System is a single, unified medical device product for treating severe emphysema. It consists of the Spiration Valve (an umbrella-shaped one-way endobronchial valve) and the associated Bronchoscopic Lung Volume Reduction (BLVR) procedure. The system is supported by patient-facing tools including a Patient Eligibility Screener questionnaire and a Physician Finder service. Patient education is provided through testimonial stories. The product is not a platform with multiple modules—it is a focused medical device system with supporting patient resources.

Differentiator

Problem solved

Functional benefit

Brands

• Spiration Valve System: A minimally invasive endobronchial valve therapy system for treatment of severe emphysema. The system uses one-way umbrella-shaped valves placed in targeted airways to redirect air from diseased lung regions to healthier ones.

Products and services

• Spiration Valve System Endobronchial valve therapy system for treating severe emphysema, consisting of umbrella-shaped one-way valves placed bronchoscopically in targeted airways to redirect air from diseased lung regions to healthier areas, reducing hyperinflation and improving breathing. Sold to hospitals and specialty clinics for use by pulmonologists.
• Spiration Valve The individual umbrella-shaped one-way nitinol valve component of the Spiration Valve System, featuring small airway anchors, an umbrella design for one-way air redirection, and compatibility with a removal rod for potential extraction.
• Bronchoscopic Lung Volume Reduction (BLVR) Procedure A minimally invasive bronchoscopic treatment procedure that places Spiration Valves in diseased airways to redirect air from damaged lung parts to healthier parts, providing improved breathing and quality of life for severe emphysema patients.

Quantifiable outcome

• 12.1% significant improvement in FEV1 (forced expiratory volume in one second)
• +3 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Emphysema Foundation of AmericacoreStrategic or Co-development Partner · 15 July 2021Olympus and Emphysema Foundation of America collaborated on a Virtual Lung Health Education Series to educate patients about lung health and treatment options including the Spiration Valve System.
• COPD FoundationcoreStrategic or Co-development Partner · 3 December 2020Olympus partnered with COPD Foundation to serve the emphysema patient community, providing education and awareness resources for patients with Chronic Obstructive Pulmonary Disease.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Pulmonx: Pulmonx markets the Zephyr Endobronchial Valve, the direct head-to-head competitor to the Spiration Valve System for endobronchial lung volume reduction in severe emphysema patients. Both compete for the same pulmonologists, same patient population, and same payer contracts, making this the closest comparable.

Broad incumbents

• Olympus Corporation: Spiration's parent company is the ultimate corporate parent and a global medical device incumbent with a broad respiratory and endoscopy portfolio. While Olympus manufactures the Spiration Valve, its GI and surgical endoscopy businesses dwarf the BLVR opportunity, making Olympus a broad incumbent reference for the corporate platform.
• Boston Scientific: Boston Scientific has a meaningful interventional pulmonology and bronchoscopy-adjacent device portfolio and competes broadly for hospital pulmonary procedure budgets. While it does not directly offer an endobronchial valve, its scale and respiratory presence make it a relevant broad incumbent comparator.
• Medtronic: Medtronic operates broadly in interventional lung and respiratory care, including devices used in pulmonary procedures. Although Medtronic does not offer a competing endobronchial valve, its scale and respiratory footprint position it as a broad incumbent comparable for procedure-level competition.
• Intuitive Surgical: Intuitive Surgical dominates minimally invasive procedural medicine with the da Vinci platform; while focused on surgery rather than bronchoscopy, it competes for the same hospital capital budgets and 'minimally invasive alternative to surgery' narrative relevant to BLVR positioning.
• Teleflex: Teleflex has a significant respiratory and airway management portfolio (e.g., endotracheal tubes, bronchoscopy supplies) that competes for hospital respiratory budgets. While not a direct valve competitor, it is a relevant comparable for airway management device economics and sales channels.

Emerging players

• CONMED: CONMED has a respiratory and pulmonary medicine portfolio that includes airway management and bronchoscopy-adjacent devices. It is a relevant emerging/incumbent player in the interventional pulmonology supply ecosystem, though it does not directly compete in endobronchial valves.
• Merit Medical Systems: Merit Medical manufactures devices used in interventional procedures including bronchoscopy-adjacent and pulmonary applications. It is a partial-overlap comparable given its presence in the procedural pulmonology supply chain rather than direct valve competition.
• Penumbra: Penumbra has expanded into interventional pulmonology with its embolization technologies (e.g., Lightning systems). It is an emerging player in the broader interventional pulmonary space, partially overlapping with the hospital and pulmonologist accounts targeted by Spiration.
• Cook Medical: Cook Medical supplies interventional pulmonology devices, including stents and airway-related products used in similar bronchoscopic procedures. It is a partial-overlap peer for the interventional pulmonology ecosystem that Spiration's customers operate in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/SpirationValve

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about spiration, inc. dba olympus respiratory america